Reimbursement euflexxa® Therapy and Insurance Coverage Therapy with euflexxa is covered by most insurance providers. Reimbursement procedures vary from provider to provider and plan to plan. You should check with your physician's staff and your insurer before beginning treatment. Here are the suggestions when you contact an insurance company: Identify euflexxa® first by NAME. Most insurance companies recognize euflexxa®. If not try, hyaluronic acid or sodium hyaluroante. If euflesxxa is not recognized by name: ask the service rep to check under the category "viscosupplementation" or "synovial fluid replacement" - euflexxa® belongs to this class of devices. If viscosupplementation and euflexxa® are not recognized: Try providing a Pseudo-DIN or PIN provided by the Atlantic Pharmaceutical Services (APFI) 96599996. euflexxa® is approved by Health Canada as a medical device and, as such, does not have a Drug Identification Number (DIN), only a Pseudo-DIN or PIN. At this point, follow steps #1 to #3. If the drug card rejects euflexxa®: This does NOT mean that the patient is not covered. Simply, patients may be required to fill out an "Insurance Claims" form to apply for reimbursement under the extended health portion of their benefit plan. euflexxa® Insurance Contacts Company / Employee Claims Telephone Number Comments Canadian Forces Military Pharmacy Formulary Covered under health benefits Empire Life 1-800-267-0215 euflexxa® -Viscosupplement-Injection-Indicate which joint-Medical Supply Great West Life 1-800-957-9777 euflexxa® recognized by name Treated as a drug for coverage (e.g. 80%, 90%, 100%) Pseudo DIN# 96599996 Green Shield 1-888-711-1119 Covered under extended health benefits-Viscosupplement Injection Industrial Alliance 1-877-422-6487 Not a drug or medical device, recognized by class and by name! Special Product! Manulife Financial 1-800-268-6195 euflexxa® recognized by name Pseudo DIN# 96599996 Medavie Blue Cross 1-800-667-4511 Mention euflexxa® is not a drug Recognized as a synovial fluid replacement/viscosupplement Pseudo DIN# 96599996 NIHB (First Nations and Inuit Health) Exceptional product status if the criteria is met. Ontario Blue Cross 1-800-234-8881 euflexxa® or Synovial Fluid Replacement Standard Life-Calgary 403-296-9400 Viscosupplement-Injection (not a drug) Note: max 3 injections per limb/lifetime! Standard Life-Ontario 1-800-465-2581 Viscosupplement-injection (not a drug) Sun Life Financial 1-800-361-6212 Mention that euflexxa® is an INJECTION Treated as a drug for coverage (e.g. 80%, 90%, 100%) Pseudo DIN# 96599996 Veterans Affairs Canada Covered under ID # 96599996 WSIB - Workers Compensation Patient pays direct and submits claim to be assessed on an exception basis. Recommended submission: physician letter, prescription and invoice for euflexxa®

	euflexxa® success story from Oylmpic Hero, Bruce Jenner ©2005-2008 Registered Trademark of Ferring BV. All rights reserved.	Ferring Inc. | Privacy Policy | Legal Disclaimer
	Important Treatment Consideration euflexxa® (1% sodium hyaluronate) is indicated for the treatment of knee pain due to osteoarthritis (OA). It is used in people who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. euflexxa® should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. In a randomized, double-blind, multicenter clinical trial, the only adverse event reported with euflexxa® at an incidence greater than 5% was arthralgia (joint pain) (8.75%). Temporary knee pain and swelling may occur after injection with euflexxa®. The safety and effectiveness of injecting euflexxa® into the knee together with other injectable medications or into joints other than the knee have not been studied. The safety and effectiveness of treatment cycles of fewer than 3 injections or of repeated treatment cycles with euflexxa® have not been established. Strict aseptic technique must be followed to avoid joint infection.